The Drugs Controller General of India (DCGI) has approved the market authorization of India’s first quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer. The Serum Institute of India (SII) will produce this vaccine. CEO of The Serum Institute of India Adar Poonawalla tweeted the information. For the first time, an inexpensive and widely available HPV vaccination made in India will be available to treat cervical cancer in female patients. Later this year, SII hopes to launch it, and we are grateful to the DCGI, MoHFW INDIA, for their approval.
Following an assessment of the clinical trial results for the vaccine, the National Technical Advisory Group on Immunization (NTAGI) recently gave its approval to the qHPV. The Quadrivalent Human Papillomavirus (qHPV) vaccine against cervical cancer, which was produced domestically by Serum Institute of India (SII), was recommended for standard market authorization on June 15. After the vaccine’s phase 3 data were deemed to be satisfactory, suggestions were made.
Important Takeaways For All Competitive Exams:
Did you know that every planet in our solar system has its own special features…
Did you know that some herbs are so powerful and useful that people have given…
Tensions rise in the Israel-Iran conflict the situation is tense. Analysts and policymakers are closely…
Hical Technologies has secured a long term contract from Dassault Aviation to produce critical parts…
India has officially notified the standards for green ammonia and green methanol under the National…
The 2nd edition of the World Para Athletics Grand Prix 2026 in New Delhi. And…